Cannabis Law Report

JUNE 5, 2019

Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients. Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. Data Highlights.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. What about other medical cannabis products? What do experts say? PDF Version.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Otherside Farms

JANUARY 24, 2019

Federal regulators have approved two clinical studies testing whether a marijuana-based epilepsy drug may help prevent seizures among epileptic children. Although both studies will enroll 25 patients initially, the U.S. Source: FDA Approves Marijuana-Based Epilepsy Drug For Use On Kids In Clinical Trials. In the upcoming U.S.

Clinical Trials 45

Clinical Trials Epilepsy Marijuana Pharmaceutical 45

MMJ Recs

NOVEMBER 17, 2023

This article explores the profound impact of MMJ on Maryland communities, shedding light on the medical marijuana benefits experienced by patients and the positive effects it has had on the state’s communities. It has improved the quality of life for those dealing with chronic pain, nausea, seizures, and other medical conditions.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Cannabis Law Report

JANUARY 16, 2022

Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) previously approved a prescription medicine derived from cannabis in 2014 to treat muscle spasms and spasticity from multiple sclerosis. Sativex was developed by GW Pharmaceuticals, a maker of cannabinoid therapeutics based in Ireland.

Research and Development 98

Research and Development Pharmaceutical Epilepsy Medicine 98

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. “Our Work with U.S.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

JULY 24, 2019

Our clinics are based on the premise that patients are treated by our world-renowned specialists in the relevant condition. We have the expertise to prescribe medicinal cannabis in a way that fits in with other more conventional treatments as and when we judge that to be in the best interest of the patients.

Epilepsy 40

Epilepsy Medicine Treatment Patients 40

Cannabis Law Report

DECEMBER 1, 2019

A young girl with a drug-resistant form of epilepsy is believed to be the first and only patient in Singapore who has been given approval to use cannabis-derived medication. The move follows approvals by lawmakers in the United States to use the medication to treat rare kinds of childhood epilepsy in that country.

Epilepsy 59

Epilepsy Cannabinoids Therapy Treatment 59

Cannabis Law Report

AUGUST 24, 2019

The report reveals… MGC Pharmaceuticals is set to kick off a controlled trial to discover if its medical cannabis product for the treatment of drug-resistant epilepsy has any impact on driving performance.

Epilepsy 45

Epilepsy Pharmaceutical Data Safety 45

Freedom Leaf

OCTOBER 15, 2018

On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. Frontier Data predicts total sales of all CBD products in the U.S. Frontier Data predicts total sales of all CBD products in the U.S.

DEA 51

DEA CBD Pharmaceutical Epilepsy 51

Veriheal

AUGUST 31, 2020

Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death. Bonaventure University and George Washington University School of Medicine. . School: University of Maryland.

Research and Development 117

Research and Development Education Agriculture Patients 117

CannaTech

AUGUST 9, 2018

We are delighted to introduce you to some new friends set to make a big impact on the medical cannabis advocacy scene… the creators of a new documentary called Separating the Strains ; a deeply personal narrative that charts the reality of living with epilepsy, with and without cannabis medication as a treatment option.

Strains 69

Strains Epilepsy Advocacy Medicine 69

Veriheal

MARCH 23, 2023

Aside from Japan legalizing medical marijuana and forging a legal pathway that enables patients to use drugs made from cannabis plants, the amended legal law also seeks to criminalize the use of marijuana. Japan’s latest Cannabis Control Law revisions would apply to pharmaceutical-grade medicinal cannabis products.

Legalization 66

Legalization Marijuana Clinical Trials Seed-To-Sale 66

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

For example, many anti-anxiety pharmaceuticals are habit-forming, entail significant negative side effects, and can also cause physical problems such as diminished mobility or coordination. Ultimately, cannabis for mental health seems to boil down to questions of individual patient suitability. CBD for Anxiety.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

The Cannigma

JUNE 15, 2021

Some healthcare professionals are already encouraged by what is known, much of it anecdotal accounts from patients in their practices. The first clinical research done on CBD as a potential treatment for epilepsy was in 1980, but the information gleaned didn’t make its way to the public eye until decades later. Shutterstock).

CBD 122

CBD Research and Development Epilepsy Extraction 122

Leaf Science

JULY 23, 2019

In the UK, cannabis was legalized for medicinal purposes in 2018 which saw patients of epilepsy and multiple sclerosis able to access pharmaceutical cannabis derivatives such as Sativex and Epidiolex.

Strains 74

Strains Cannabinoids Epilepsy THC 74

Veriheal

DECEMBER 28, 2021

This is according to recent data from a report published by Market Research Future (MRT) – a pioneer in market analysis. For example, pharmaceutical-grade cannabis is being sold across the fast-evolving retail pharmacy landscape. by the year 2027 , at which point the market could be worth a staggering $33.2 Alzheimer’s.

Research and Development 98

Research and Development Chronic Pain Treatment Medicine 98

Veriheal

MAY 31, 2022

According to data released by the Centers for Disease Control and Prevention , there were an estimated 2,620 opioid overdose deaths in Texas between Aug. A 2019 study found that 76% of patients in the U.S. fill an opioid prescription after having surgery compared to just 11% of Swedish patients.

Programs 52

Programs Chronic Pain Treatment Conditions 52

Veriheal

JULY 5, 2021

sales last year—a recent study has confirmed that these cannabinoid receptor-binding molecules offer different levels of symptomatic relief for nausea patients. . The self-reported data was logged between June 6, 2016, and July 8, 2019. Anti-nausea (antiemetic) therapies are often prescribed to nausea patients. Motion sickness.

THC 52

THC CBD Treatment Cannabinoids 52

Cannabis Law Report

JUNE 1, 2021

As we prepare for a potential world-class launch of Vicineum, I strongly believe that these leaders will not only bring diverse and invaluable expertise to our team but will also drive the Company to continue executing our mission to save and improve the lives of patients with cancer.”. CAMBRIDGE, Mass.–(BUSINESS About Sesen Bio.

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

WeedAdvisor

APRIL 8, 2019

The only actual confirmed benefit of CBD is its effect on Lennox Gastaut Syndrome and Dravet Syndrome – two severe types of epilepsy that do not typically respond to conventional treatment. This led to Epidiolex, the first FDA-approved pharmaceutical drug derived from CBD for the sole purpose of treating LGS and Dravet.

Food 40

Food CBD Research and Development Treatment 40

Cannabis Law Report

MARCH 3, 2020

Hot coffee, friendly staff, and medical cannabis eagerly greet patients and guests on Feburary 15, 2020 at the Grand Opening of MÜV Dispensary on Ninth Avenue in Pensacola, Florida. . We strive to make a firsthand connection with every patient or caretaker to provide them with reliable and effective cannabis based therapies.

Dispensary 64

Dispensary Patients Cannabis Wellness and Beauty 64

CannaTech

OCTOBER 14, 2018

billion by 2022, according to New Frontier Data, a premier cannabis data analytics firm. Food and Drug Administration’s approval of a CBD-based drug that treats patients with rare forms of epilepsy by reducing seizures. In the U.S. One of the best examples is a recent study that led to the U.S.

Hemp 53

Hemp Research and Development Agriculture Seed-To-Sale 53

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Epilepsy Behav. Consumers spent roughly $31.3 increase in annual sales.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

JANUARY 20, 2022

Academic trials of oral psilocybin revealed considerable variability in patients’ absorption and metabolism rates at identical doses, which may result in unpredictable pharmacokinetics and pharmacodynamics. Third-party clinical studies investigating oral psilocybin have reported compelling anti-depressant effects. II is a $287.5

Therapy 52

Therapy Research and Development Business Access 52

Cannabis Law Report

NOVEMBER 15, 2021

–(BUSINESS WIRE)– #earnings — Virpax ® Pharmaceuticals, Inc. Finally, we recently acquired the worldwide rights to VRP324, which is an intranasal pharmaceutical-grade cannabidiol product candidate for the management of epilepsy in children (rare pediatric disease) and adults. About Virpax Pharmaceuticals.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

CannaTech

SEPTEMBER 23, 2019

The acceptance of medical cannabis by clinicians, researchers and government bodies is fairly universal, and patients have benefited from widespread access to full-spectrum cannabis in flower and oil form. Israel’s approach to cannabis has contributed to reducing stigma and increasing access for patients around the world.

Patients 79

Patients Policy Clinical Trials Research and Development 79

Cannabis Law Report

DECEMBER 20, 2021

First Patient Expected to be Enrolled by Q2 of 2022. Data To Support Regulatory Filings in the United States. –(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. The study will take place in Canada with a CTA filing and enrollment of the first patient anticipated by Q2 of 2022. BERWYN, Pa.–(BUSINESS

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Data 52

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. At the same time, the outlook on cannabis research data is largely positive. Refractory paediatric epilepsy.

Research and Development 52

Research and Development Medicine Access Media 52

SMPL

MAY 26, 2020

Miller spent the months after this meeting leading hundreds of CBD seminars for farmers; Dr. Kerr began informal patient surveys to track how CBD made people feel; and as he finished his book, Mr. Lee often traveled around with Mr. Laughter and Mr. Ringo’s high-CBD plants and seeds, spreading the gospel at pot shops across the West.

CBD 40

CBD Research and Development Pharmaceutical Seed-To-Sale 40

Cannabis Law Report

NOVEMBER 10, 2021

–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. Once the Envelta IND-enabling studies are submitted to the FDA, the data may be cross-referenced to our cancer pain and PTSD INDs. About Virpax Pharmaceuticals. In October 2021, Virpax announced that a $1.87 Forward-Looking Statement.

Research and Development 52

Research and Development Chronic Pain Pharmaceutical Clinical Trials 52

Cannabis Law Report

OCTOBER 26, 2019

The TGA does not evaluate any data relating to the trial. iv Named-patient and compassionate use proceduresThe TG Act provides mechanisms that allow individuals to gain limited access to UTGs (defined in Section II.iii). The institution at which the trial will be conducted gives the final approval.

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45

Cannabis Law Report

JULY 12, 2019

Side effects were very prevalent in 79% of all patients taking a refined CBD product, some of which were severe like thrombocytopenia and transaminase elevations in the liver. Review: During an open-label trial of pure CBD with Lennox-Gastaut and Dravet patients, 79% of all patients reported side effects.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

Green Relief

MAY 13, 2018

A 2014 study found that traumatic brain injury ( TBI ) patients who tested positive for THC were more likely to survive with less impairment than TBI patients who abstained from marijuana. It is the most commonly identified cause of epilepsy among adults. Highlights: According to a U.S. million Americans annually. The patent.

THC 64

THC CBD Cannabinoids Research and Development 64

Green Relief

MAY 12, 2018

A 2014 study found that traumatic brain injury ( TBI ) patients who tested positive for THC were more likely to survive with less impairment than TBI patients who abstained from marijuana. It is the most commonly identified cause of epilepsy among adults. Highlights: According to a U.S. million Americans annually. The patent.

Research and Development 40

Research and Development Cannabinoids Therapy CBD 40